Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CYP2D6 genotype and plasma levels of haloperidol and reduced haloperidol in Japanese
Autore:
Kondo, T; Suzuki, A; Mihara, K; Yasui, N; Kaneko, S;
Indirizzi:
Hirosaki Univ Hosp, Dept Neuropsychiat, Hirosaki, Aomori 036, Japan Hirosaki Univ Hosp Hirosaki Aomori Japan 036 Hirosaki, Aomori 036, Japan
Titolo Testata:
MOLECULAR MEDICINE: NOVEL FINDINGS OF GENE DIAGNOSIS, REGULATION OF GENE EXPRESSION, AND GENE THERAPY
, volume: 1172, anno: 1999,
pagine: 81 - 86
SICI:
0531-5131(1999)1172:<81:CGAPLO>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
DEBRISOQUINE HYDROXYLATION PHENOTYPE; POLYMORPHIC DRUG OXIDATION; POOR METABOLIZERS; DISPOSITION; ALLELE;
Keywords:
enzyme activity; metabolism; mutated allele; steady-state kinetics;
Tipo documento:
Article
Natura:
Collana
Settore Disciplinare:
Clinical Medicine
Citazioni:
11
Recensione:
Indirizzi per estratti:
Indirizzo: Kondo, T Hirosaki Univ, Sch Med, Dept Neuropsychiat, 5 Zaifu Cho, Hirosaki, Aomori 0368562, Japan Hirosaki Univ 5 Zaifu Cho Hirosaki Aomori Japan 0368562 62, Japan
Citazione:
T. Kondo et al., "CYP2D6 genotype and plasma levels of haloperidol and reduced haloperidol in Japanese", INT CONGR S, 1172, 1999, pp. 81-86

Abstract

Background The usefulness of cytochrome P450 (CYP) 2D6 genotype for the prediction of the steady-state plasma concentrations (C-ss) of haloperidol and reduced haloperidol was examined for rational haloperidol treatment in Japanese. Methods. The C-ss of haloperidol and reduced haloperidol were measured in 101 patients receiving 6-36 mg/day of oral haloperidol. The CYP2D6 genotypewas determined by identification of CYP2D6 *1 (nonmutated allele) and CYP2D6 *3, *4, *5, *10 (mutated alleles). Results. The subjects were divided into three groups; 0 mutated alleles (41 cases), 1 mutated allele (47 cases) and 2 mutated alleles (13 cases). Thecorrected C-ss of haloperidol by dose/body weight in the three groups were8.6 +/- 3.9, 11.2 +/- 4.2 and 11.5 +/- 6.0 ng/ml. respectively (1 mutated allele > nonmutation: p < 0.05), and those for reduced haloperidol were 2.3+/- 1.1, 3.9 +/- 1.8 and 4.0 +/- 2.4 ng/ml, respectively (1 and 2 mutated alleles > nonmutation: p < 0.05). Conclusions. These results suggest that the C-ss of haloperidol and reduced haloperidol are at least partly dependent on the CYP2D6 activity, although the CYP2D6 genotype does not necessarily predict the C-ss of both compounds since large overlaps in the C-ss were observed among the three differentpatient groups.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/20 alle ore 01:20:09